PMID- 11801304
OWN - NLM
STAT- MEDLINE
DCOM- 20020226
LR  - 20190816
IS  - 0165-4608 (Print)
IS  - 0165-4608 (Linking)
VI  - 132
IP  - 1
DP  - 2002 Jan 1
TI  - Contribution of cytogenetics and in situ hybridization to the study of monoclonal 
      gammopathies of undetermined significance.
PG  - 25-9
AB  - Monoclonal gammopathies of undetermined significance (MGUS) are characterized by 
      the presence of a monoclonal protein in serum in quite asymptomatic patients. Ten 
      to 33% of MGUS patients eventually will develop overt multiple myeloma, but no 
      single laboratory test exists that can predict changes toward a malignant 
      evolution. The aim of the present study was to apply conventional cytogenetics, 
      the MAC (morphology, antibody, chromosome) method and fluorescence in situ 
      hybridization (FISH) techniques in a series of 50 MGUS patients and 4 
      "smoldering" multiple myeloma patients to test the usefulness of their approaches 
      as predictive methodologies. All patients studied by conventional cytogenetics 
      presented a normal karyotype independent of the culture conditions used. The MAC 
      method revealed that all mitotic cells showing a normal karyotype were positive 
      for anti-MOP7 or anti-CD3 in 12 patients studied. In addition, two of them 
      presented a numerical abnormality detected by FISH. Using a FISH technique with 
      direct labeled centromeric probes for chromosomes 3, 7, 11, and 18 we showed a 
      numerical abnormality in eight of 35 patients (23%) with a normal karyotype. The 
      common occurrence of MGUS and the fact that they may evolve toward 
      lymphoproliferative disorders displays the importance of being able to identify 
      laboratory results that are capable of predicting the evolution of these 
      patients. In the literature, patients who presented an IgA peak of immunoglobulin 
      type have been associated with a higher risk of evolving to a malignant 
      condition. Our study shows the correlation of MGUS patients who presented 
      monosomy 18 with the presence of an immunoglobulin peak of the IgA type. 
      Prospective follow-up is needed to evaluate the clinical value of monosomy 18 as 
      a predictive factor for defining a high risk of malignant transformation in MGUS 
      patients.
FAU - Lloveras, Elisabet
AU  - Lloveras E
AD  - Laboratori de Citologia Hematologica, Laboratori de Referencia de Catalunya, 
      Departament de Patologia, Hospital del Mar, IMAS, Barcelona, Spain. 
      elloveras@hotmail.com
FAU - Sole, Francesc
AU  - Sole F
FAU - Florensa, Lourdes
AU  - Florensa L
FAU - Besses, Carles
AU  - Besses C
FAU - Espinet, Blanca
AU  - Espinet B
FAU - Gil, Miguel
AU  - Gil M
FAU - Perez-Vila, Ma Encarnacion
AU  - Perez-Vila ME
FAU - Pedro, Carmen
AU  - Pedro C
FAU - Abella, Eugenia
AU  - Abella E
FAU - Sans-Sabrafen, Jordi
AU  - Sans-Sabrafen J
FAU - Woessner, Soledad
AU  - Woessner S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Genet Cytogenet
JT  - Cancer genetics and cytogenetics
JID - 7909240
RN  - 0 (CD3 Complex)
RN  - 0 (Paraproteins)
RN  - EC 1.11.1.7 (Peroxidase)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aneuploidy
MH  - Bone Marrow/pathology
MH  - CD3 Complex/immunology
MH  - Cells, Cultured
MH  - Chromosome Aberrations
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Interphase/genetics
MH  - Karyotyping
MH  - Middle Aged
MH  - Monoclonal Gammopathy of Undetermined Significance/*genetics/pathology
MH  - Monosomy/genetics
MH  - Multiple Myeloma/*genetics/pathology
MH  - Paraproteins/genetics
MH  - Peroxidase/immunology
EDAT- 2002/01/22 10:00
MHDA- 2002/02/28 10:01
CRDT- 2002/01/22 10:00
PHST- 2002/01/22 10:00 [pubmed]
PHST- 2002/02/28 10:01 [medline]
PHST- 2002/01/22 10:00 [entrez]
AID - S0165460801005118 [pii]
AID - 10.1016/s0165-4608(01)00511-8 [doi]
PST - ppublish
SO  - Cancer Genet Cytogenet. 2002 Jan 1;132(1):25-9. doi: 
      10.1016/s0165-4608(01)00511-8.